GlassScriptPhysician profile
James John Kosik
NPI 1497783468
$18,268.97
in general payments reported to CMS, 2019-2025
37 companies · $1,986 in 2025
The $1,986 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,582 · 2020: $1,647 · 2021: $2,551 · 2022: $3,191 · 2023: $3,640 · 2024: $2,671 · 2025: $1,986.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,265 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,265.45 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,145.57 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $2,583.25 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $1,847.98 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $1,501.66 | 2019-2024 | Spravato, Xarelto |
| Abbvie INC. | $992.49 | 2021-2024 | |
| Amgen INC. | $753.31 | 2019-2025 | Repatha, Repatha, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $726.34 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $693.42 | 2019-2025 | Jardiance, Synjardy |
| Lilly USA, LLC | $654.89 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Phathom Pharmaceuticals, INC. | $568.28 | 2024-2025 | Voquezna |
| Amarin Pharma, INC. | $527.44 | 2019-2021 | |
| Esperion Therapeutics, INC. | $439.74 | 2021-2025 | Nexletol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $348.40 | 2019-2025 | Xifaxan |
| Axsome Therapeutics, INC. | $224.15 | 2024-2025 | Sunosi |
| Merck Sharp & Dohme LLC | $223.59 | 2019-2022 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Kosik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.